Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Total Assets of $7.59 billion for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +8.7% in Total Assets from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $985.52 million | Q3 2010: $1.24 billion | Q1 2011: $1.26 billion | Q2 2011: $1.28 billion | Q3 2011: $1.30 billion | Q1 2012: $1.30 billion | Q2 2012: $1.53 billion | Q3 2012: $1.57 billion | Q1 2013: $1.60 billion | Q2 2013: $1.60 billion | Q3 2013: $1.62 billion | Q1 2014: $2.34 billion | Q2 2014: $2.35 billion | Q3 2014: $2.44 billion | Q1 2015: $3.66 billion | Q2 2015: $3.65 billion | Q3 2015: $3.62 billion | Q1 2016: $3.67 billion | Q2 2016: $3.09 billion | Q3 2016: $3.84 billion | Q1 2017: $3.94 billion | Q2 2017: $4.02 billion | Q3 2017: $4.58 billion | Q1 2018: $4.60 billion | Q2 2018: $4.62 billion | Q3 2018: $4.70 billion | Q1 2019: $4.44 billion | Q2 2019: $4.39 billion | Q3 2019: $4.56 billion | Q1 2020: $4.72 billion | Q2 2020: $5.30 billion | Q3 2020: $6.16 billion | Q1 2021: $5.81 billion | Q2 2021: $5.90 billion | Q3 2021: $5.98 billion | Q1 2022: $6.06 billion | Q2 2022: $6.15 billion | Q3 2022: $6.26 billion | Q1 2023: $6.43 billion | Q2 2023: $6.56 billion | Q3 2023: $6.76 billion | Q1 2024: $6.87 billion | Q2 2024: $7.07 billion | Q3 2024: $6.85 billion | Q1 2025: $7.15 billion | Q2 2025: $7.46 billion | Q3 2025: $7.61 billion.
- Over the full 17 years of available data (2009 to 2025), BIOMARIN PHARMACEUTICAL INC's Total Assets has grown by 728.0%.
- Historical annual values: Fiscal year 2025: $7.59 billion | Fiscal year 2024: $6.99 billion | Fiscal year 2023: $6.84 billion | Fiscal year 2022: $6.38 billion | Fiscal year 2021: $6.00 billion | Fiscal year 2020: $5.85 billion | Fiscal year 2019: $4.69 billion | Fiscal year 2018: $4.43 billion | Fiscal year 2017: $4.63 billion | Fiscal year 2016: $4.02 billion | Fiscal year 2015: $3.73 billion | Fiscal year 2014: $2.48 billion | Fiscal year 2013: $2.24 billion | Fiscal year 2012: $1.57 billion | Fiscal year 2011: $1.31 billion | Fiscal year 2010: $1.26 billion | Fiscal year 2009: $917.16 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: